TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8281566

Group type: EXPERIMENTAL
Intervention: Conventional bite-wing radiography
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Digital bite-wing radiography
Number of subjects: 168

Group type: COMPARATOR
Intervention: Clinical examination alone
Number of subjects: 168
Study: 3493333

Group type: EXPERIMENTAL
Intervention: PAG-PVG stimulation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Thalamic sensory relay nuclei stimulation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Morphine sulfate (blind, placebo-controlled protocol)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous naloxone (double-blind, placebo-controlled protocol)
Number of subjects: 45
Study: 29979640

Group type: EXPERIMENTAL
Intervention: LGBT women veterans
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Non-LGBT women veterans
Number of subjects: 1391
Study: 28807006

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP) - an obesity prevention programme
Number of subjects: 1324
Study: 26584951

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100/25 mg TID for 40 weeks (including 2 weeks of dose escalation)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo TID for 40 weeks
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100/25 mg TID for 40 weeks (after initial 40 weeks of treatment)
Number of subjects: 446
Study: 23180405

Group type: EXPERIMENTAL
Intervention: Ferrous ascorbate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Colloidal iron
Number of subjects: 73
Study: 22035675

Group type: EXPERIMENTAL
Intervention: Higher resting systolic BP levels in girls
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Higher resting diastolic BP levels in young girls (8-11 years)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Age
Number of subjects: 235
Study: 18779882

Group type: EXPERIMENTAL
Intervention: Dysport 200 U/ml
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dysport 150 U/ml
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dysport 100 U/ml
Number of subjects: 36

Group type: COMPARATOR
Intervention: Botox 100 U/ml
Number of subjects: 36
Study: 16554494

Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the G-allele
Number of subjects: 226

Group type: COMPARATOR
Intervention: Controls (non-carriers)
Number of subjects: 226
Study: 12942590

Group type: EXPERIMENTAL
Intervention: Sinemet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Grifoparkin
Number of subjects: 30
Study: 10690944

Group type: EXPERIMENTAL
Intervention: Half dose epinephrine (0.375 microg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Full dose epinephrine (0.75 microg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epinephrine studies (both doses)
Number of subjects: 10
Study: 9513252

Group type: EXPERIMENTAL
Intervention: Albumin-impregnated prostheses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-impregnated polyester knitted vascular prostheses
Number of subjects: 100
Study: 8191053

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy with Naftidrofuryl, 1 session per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy with Naftidrofuryl, 2 sessions per day
Number of subjects: 0
Study: 2873094

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 56
Study: 30362133

Group type: EXPERIMENTAL
Intervention: Structured peer‐assisted learning program using deliberate practice (Group A, n=15)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Unstructured peer‐supported environment (Group B, n=15)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Assessment‐only control group (Group C, n=13)
Number of subjects: 43
Study: 28339745

Group type: EXPERIMENTAL
Intervention: Chronic nasal Staphylococcus aureus carriage (CNSAC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chronic nasal Staphylococcus aureus carriage (CNSAC) in generalized GPA
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chronic nasal Staphylococcus aureus carriage (CNSAC) in early systemic GPA during immunosuppression
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prophylactic trimethoprim/sulfamethoxazole (T/S)
Number of subjects: 200
Study: 26027612

Group type: EXPERIMENTAL
Intervention: Cyclosporine (2.5 mg/kg intravenous infusion)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study: 23215966

Group type: EXPERIMENTAL
Intervention: Short treatment (three x two-hour sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 20
Study: 21415156

Group type: EXPERIMENTAL
Intervention: Aspirin at baseline
Number of subjects: 100

Group type: COMPARATOR
Intervention: No aspirin at baseline
Number of subjects: 100
Study: 19722788

Group type: EXPERIMENTAL
Intervention: Immediate-restoration group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: One-stage group (n = 30)
Number of subjects: 60
Study: 17321312

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 8146

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 8146

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 8146
Study: 15475125

Group type: EXPERIMENTAL
Intervention: Powered wheelchair manoeuvres
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Forward steering
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Backwards steering
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Left steering
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Right steering
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: JASA analysis
Number of subjects: 10
Study: 11504589

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (sham hypoxic trainer)
Number of subjects: 9
Study: 9659472

Group type: EXPERIMENTAL
Intervention: Functional tape
Number of subjects: 50

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 50
Study: 7645637

Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin
Number of subjects: 606
Study: 2524684

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 27 mg plus ethinyl estradiol 0.035 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Danazol 600 mg/day
Number of subjects: 23
Study: 22216503

Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg)
Number of subjects: 10
Study: 30957449

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupropion hydrochloride sustained-release tablets
Number of subjects: 100
Study: 29079252

Group type: EXPERIMENTAL
Intervention: Intensive therapy (HbA1c <6.2% [44.3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease])
Number of subjects: 2542

Group type: COMPARATOR
Intervention: Conventional therapy (targets: HbA1c <6.9% [52.0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease])
Number of subjects: 2542
Study: 25971655

Group type: COMPARATOR
Intervention: Pre-operative education
Number of subjects: 209

Group type: COMPARATOR
Intervention: Mini-invasive surgery
Number of subjects: 209
Study: 23239680

Group type: EXPERIMENTAL
Intervention: Milk supplementation (24 oz/day, one 16-oz dose immediately post-RT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Isocaloric carbohydrate (100% fruit juice)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 108
Study: 21184185

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) combination
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Formoterol fumarate (F)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study: 19028124

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/d)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Alendronate (10 mg/d)
Number of subjects: 428
Study: 17270315

Group type: EXPERIMENTAL
Intervention: Eflornithine cream plus laser treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Laser treatment alone (placebo cream)
Number of subjects: 31
Study: 15050263

Group type: EXPERIMENTAL
Intervention: LASEK with a larger (6.5 mm) zone with 8.0 mm blend zone
Number of subjects: 19

Group type: COMPARATOR
Intervention: LASEK with a conventional (6.0 mm) optical zone
Number of subjects: 19
Study: 11699049

Group type: EXPERIMENTAL
Intervention: Stress hormone infusion
Number of subjects: 16
Study: 9140509

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITBN)
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Control group (no ITBN)
Number of subjects: 1479
Study: 7950114

Group type: EXPERIMENTAL
Intervention: True Vista bifocal lens (group I)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Accurasee bifocal lens (group II)
Number of subjects: 34
Study: 3165436

Group type: EXPERIMENTAL
Intervention: Levodopa sustained-release (S. R.) formulations
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard preparation of levodopa
Number of subjects: 2
Study: 31148332

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 64
Study: 28587581

Group type: EXPERIMENTAL
Intervention: 40 mg enalapril (E) for 4 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril (E) with or without hydrochlorothiazide (acute treatment)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 20 mg enalapril (E) + 16 mg candesartan (EC) for chronic treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Higher plasma ACE concentration
Number of subjects: 34
Study: 25246074

Group type: EXPERIMENTAL
Intervention: HA viscosupplementation (3 weekly intra-articular injections of HA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 86
Study: 24168767

Group type: EXPERIMENTAL
Intervention: Frequent exacerbators (≥ 2 exacerbations during study treatment)
Number of subjects: 7376

Group type: EXPERIMENTAL
Intervention: Exacerbation-related hospitalisations
Number of subjects: 7376
Study: 21839994

Group type: EXPERIMENTAL
Intervention: Circumferential radiofrequency ablation (RFA)
Number of subjects: 29
Study: 18430744

Group type: EXPERIMENTAL
Intervention: Lornoxicam (0.1 mg kg(‐1))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 22
Study: 17161233

Group type: EXPERIMENTAL
Intervention: Inslow (palatinose-based liquid diet)
Number of subjects: 7
Study: 15243316

Group type: EXPERIMENTAL
Intervention: Eductyl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eductyl + psyllium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Psyllium
Number of subjects: 20
Study: 11317154

Group type: EXPERIMENTAL
Intervention: Supplemented Group (A) with SUPRO Isolated Soy Protein (1 g/kg body weight)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non‐Supplemented Group (B) with placebo
Number of subjects: 14
Study: 9389278

Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alfentanil 250 micrograms
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 90
Study: 7696152

Group type: EXPERIMENTAL
Intervention: CYTOPRESS semi‐automatic slide preparation system and CERVIFIP interactive scanner
Number of subjects: 701
Study: 3311924

Group type: EXPERIMENTAL
Intervention: cis‐platinum and cyclophosphamide
Number of subjects: 267

Group type: COMPARATOR
Intervention: cis‐platinum, cyclophosphamide, and doxorubicin
Number of subjects: 267
Study: 30309755

Group type: EXPERIMENTAL
Intervention: Cold tumescence anesthesia solution (4°C)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Room temperature tumescence anesthesia solution (24°C)
Number of subjects: 51
Study: 28068978

Group type: EXPERIMENTAL
Intervention: YourCall™ text message intervention (16 informational and motivational text messages delivered over 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YourCall™ text message intervention
Number of subjects: 0
Study: 27097858

Group type: EXPERIMENTAL
Intervention: Hypnosis prior to local anesthesia administration
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no hypnosis)
Number of subjects: 200
Study: 24366425

Group type: EXPERIMENTAL
Intervention: High molecular weight (HMW) urinary adiponectin excretion
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: HMW-adiponectin excretion
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: HMW-adiponectin
Number of subjects: 141

Group type: COMPARATOR
Intervention: Total adiponectin excretion
Number of subjects: 141

Group type: COMPARATOR
Intervention: Albumin excretion rate (AER)
Number of subjects: 141
Study: 22761709

Group type: EXPERIMENTAL
Intervention: Diltiazem sustained-release capsules (90 mg twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diltiazem sustained-release capsules
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diltiazem sustained-release capsules and Placebo
Number of subjects: 80
Study: 19390588

Group type: EXPERIMENTAL
Intervention: Fatty fish (n = 11)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lean fish (n = 12)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 33
Study: 17702957

Group type: EXPERIMENTAL
Intervention: Treadmill aerobic training (T‐AEX)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Attention-matched stretching intervention (CONTROL)
Number of subjects: 46
Study: 15071378

Group type: EXPERIMENTAL
Intervention: Medical emergency team intervention
Number of subjects: 2183
Study: 11845949

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tretinoin gel 0.025%
Number of subjects: 150
Study: 9751346

Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil
Number of subjects: 384
Study: 7873474

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose positive inotropes (including vesnarinone)
Number of subjects: 0
Study: 3068159

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29485340

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS)
Number of subjects: 10
Study: 28610818

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25772326

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus concurrent oral vinorelbine and capecitabine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus sequential oral vinorelbine and capecitabine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Circulating endothelial progenitors (CEP) below median
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Viable circulating endothelial cells (CEC) below median
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Circulating endothelial progenitors (CEP) above median
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Viable circulating endothelial cells (CEC) above median
Number of subjects: 66
Study: 23397148

Group type: EXPERIMENTAL
Intervention: GLM 100 mg + MTX
Number of subjects: 19

Group type: COMPARATOR
Intervention: PBO + MTX
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GLM 50 mg + MTX
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GLM 50 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GLM 100 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PBO
Number of subjects: 19
Study: 22005471

Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin (Pem/Carb)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Docetaxel/Carboplatin (Doc/Carb)
Number of subjects: 260
Study: 19695154

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 171

Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 171
Study: 16895618

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (non-acupoint site)
Number of subjects: 100
Study: 15488964

Group type: EXPERIMENTAL
Intervention: 20 mg ipsapirone orally
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.002 mg/kg intravenous clonidine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Immediate release venlafaxine (37.5 mg, b.i.d. for low-dose responders; 75 mg, b.i.d. or higher for high-dose responders)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10878071

Group type: EXPERIMENTAL
Intervention: stavudine-zalcitabine-saquinavir (soft gel capsule) [d4T-ddC-SQV(SGC)]
Number of subjects: 36
Study: 9145450

Group type: EXPERIMENTAL
Intervention: Dietary fibre and lactulose biscuits (11 biscuits containing 10 g dietary fibre, 2 g raw fibre, 8.2 g lactulose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control diet without biscuits
Number of subjects: 10
Study: 1435880

Group type: EXPERIMENTAL
Intervention: Human fetal ventral mesencephalic tissue transplantation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (one-year delay in surgery)
Number of subjects: 4
Study: 3547991

Group type: EXPERIMENTAL
Intervention: Plastic adhesive drapes
Number of subjects: 123

Group type: COMPARATOR
Intervention: No drape (Control)
Number of subjects: 123
Study: 29687268

Group type: EXPERIMENTAL
Intervention: Multiple contests (3 consecutive contests)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Single contest (1 consecutive contest)
Number of subjects: 1217
Study: 27196764

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab (first-line treatment)
Number of subjects: 525
Study: 24646647

Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 22897465

Group type: EXPERIMENTAL
Intervention: Benign Prostatic Hyperplasia Impact Index (BII)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Concept elicitation (CE) and cognitive interviewing (CI) methods
Number of subjects: 50
Study: 20388497

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (CHO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Energy-free placebo solution (PLA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (CHO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo mouth rinse (PLA)
Number of subjects: 33
Study: 18450787

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 24 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15795434

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (3.4g CLA/d in triglyceride form)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation
Number of subjects: 134
Study: 12714874

Group type: EXPERIMENTAL
Intervention: ACE genotype D/D
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ACE genotype I/I
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ACE genotype I/D
Number of subjects: 132

Group type: COMPARATOR
Intervention: EHT patients (all genotypes)
Number of subjects: 132
Study: 11188982

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8828617

Group type: EXPERIMENTAL
Intervention: Low concurrent phenylalanine (Phe) levels
Number of subjects: 118

Group type: COMPARATOR
Intervention: High concurrent phenylalanine (Phe) levels
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Lowering concurrent phenylalanine (Phe) levels over a period of 4-5 weeks
Number of subjects: 118
Study: 1364154

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 9
Study: 2996905

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily (o.d.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily (b.d.)
Number of subjects: 10
Study: 31882606

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MFT) delivered through a smartphone app for 4 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 29
Study: 29369184

Group type: EXPERIMENTAL
Intervention: Tourniquet use during the entire operation (Group 1)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Tourniquet use only at the time of cementing (Group 2)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No tourniquet use (Group 3)
Number of subjects: 59
Study: 28002896

Group type: EXPERIMENTAL
Intervention: Hybrid Hyaluronic Acid (HHA); 3 injections
Number of subjects: 48

Group type: COMPARATOR
Intervention: Platelet-Rich Plasma (PRP); 3 injections
Number of subjects: 48
Study: 25324317

Group type: EXPERIMENTAL
Intervention: 500 U abobotulinumtoxinA
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 22462424

Group type: EXPERIMENTAL
Intervention: Therapeutic continuous ultrasound (US)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham ultrasound (US)
Number of subjects: 42
Study: 20595643

Group type: EXPERIMENTAL
Intervention: Green tea beverage (4 cups/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Green tea extract (2 capsules and 4 cups water/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Green tea beverage and extract groups
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (4 cups water/d)
Number of subjects: 35